Stockwinners Market Radar for October 06, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:34 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. General Motors (GM) and United Auto Workers hit a roadblock in contract talks over the question of moving production from Mexico to plants in the U.S., The New York Times' Neal Boudette reported, citing two people familiar with the matter. The union has pressed GM to shift production of some sport utility vehicles and pickup trucks from Mexican factories in order to create and secure jobs in domestic plants, sources said. 2. A pending U.S. lawsuit over claims related to Bayer's (BAYRY) glyphosate-based herbicide Roundup has been delayed, with a new court date set for February, 2020, according to Reuters, citing the company. 3. Almost all of the major brokerage firms-Charles Schwab (SCHW), E-Trade (ETFC), Interactive Brokers (IBKR), and TD Ameritrade (AMTD)-slashed equity-trading commissions to zero this week, with Fidelity and Vanguard seem to be holding out for now, Daren Fonda wrote in this week's edition of Barron's. While customers of the companies may be delighted, analysts slashed their estimates and tried to figure out who the winners and losers would be once the dust settles, the author noted. If there is a winner, it is likely to be Schwab, though the company faces significant near-term challenges, Fonda added. 4. AT&T (T) subsidiary Warner Bros.' "Joker" earned $93.5M domestically in its debut, setting a new opening record for the month of October. The supervillain movie also raked in $140.5M from over 70 markets for a global start of $234M. Audiences gave "Joker" a B+ CinemaScore, while Rotten Tomatoes rating stands at 69%. 5. Delta Air Lines (DAL), TSMC (TSM), Visa (V), Mastercard (MA), Valero Energy (VLO) and Marathon Petroleum (MPC) saw positive mentions in this week's edition of Barron's, while Spotify (SPOT) was mentioned cautiously.

15:39 EDT Dish reaches long-term carriage agreement with Fox - Dish Network (DISH) has reached a multi-year carriage agreement with Fox Corp. (FOXA) for its owned-and-operated local stations, as well as FS1, FS2, BTN, Fox Soccer Plus and Fox Deportes. In a statement, the company said: "We appreciate our customers' patience as we worked to reach a long-term agreement that restores the Fox networks and local broadcast stations." Terms of the agreement were not disclosed.

15:30 EDT Elbit Systems awarded $153M contract - Elbit Systems announced that it was awarded a contract valued at approximately $153M to supply an Army of a country in Southeast Asia with a comprehensive, multi-layered array of Unmanned Aircraft Systems. The contract will be performed over a 22-month period. Under the contract, Elbit Systems will supply a networked multi-layered UAS solution, including more than a thousand THOR Multi-Rotor Vertical Takeoff and Landing mini-UAS, scores of Skylark LEX, Skylark 3 and Hermes 450 tactical UAS as well as Universal Ground Control Stations.

15:15 EDT Audentes Therapeutics presents new data from ASPIRO trial - Audentes Therapeutics announced new positive data from ASPIRO, the clinical trial evaluating AT132 in patients with X-Linked Myotubular Myopathy. The newly reported data include safety and efficacy assessments as of the August 7, 2019 data cut-off date for 12 patients enrolled in the ASPIRO dose escalation cohorts. The data includes 48 weeks or more of follow-up for seven patients enrolled in Cohort 1; and 24-48 weeks of follow-up for five patients in Cohort 2. Key assessments include neuromuscular function as assessed by the achievement of motor milestones and improvement in CHOP INTEND score, and respiratory function as assessed by reduction in ventilator dependence and improvement in maximal inspiratory pressure. The presentation does not include new muscle biopsy data. Patients receiving AT132 have achieved significant and durable reductions in ventilator dependence, an endpoint considered to be closely correlated with morbidity and mortality in XLMTM patients. To date, the first seven patients treated have achieved ventilator independence. All treated patients continue to show gains in neuromuscular function, with the first seven patients treated achieving the ability to rise to a standing position, or walk. AT132 has been generally well-tolerated and has shown a manageable safety profile across both dose groups. Since the last data update in May 2019, there has been one new serious adverse event in Cohort 2, an episode of joint swelling that resolved without treatment. Results to date indicate no clinically meaningful differences in the safety and tolerability profile of AT132 between the 1x1014 vg/kg and 3x1014 vg/kg dose cohorts. Next steps in the AT132 development program include the completion of enrollment and follow-up of patients in the ASPIRO pivotal expansion cohort, designed to confirm the safety and efficacy profile of AT132 at a dose of 3x1014 vg/kg, and preparations for filing of a Biologics License Application for AT132 in the United States planned in mid-2020 and filing of a Marketing Authorization Application in Europe planned for the second half of 2020.